The pro-oncogenic transcription factor STAT3 is often constitutively activated in both tumor and stromal cells
of breast cancer (BC) and other types of tumors, acting both directly on epithelial cells and on cells of the
stroma including Cancer Associated Fibroblasts. Interfering with STAT3 activity in CAFs and/or tumor cells may
thus represent an effective therapeutic strategy particularly in basal-like BC, where STAT3 activity is highly
implicated. However, despite numerous promising pre-clinical studies no STAT3 inhibitor has so far reached
the clinic. Here, I propose an RNA-based approach alternative to classical inhibitors, taking advantage of
previously developed, in vivo effective small interfering RNAs against STAT3.